Abstract
BackgroundInhibition of IL-6 receptor with tocilizumab (TCZ) is an effective strategy for treating rheumatoid arthritis (RA) patients. However, the effect of TCZ on lymphocytes remains poorly studied. Regulatory T cells...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have